MedTrace Logo

Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis

NCT03561025 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2020-11-18

No results posted yet for this study

Summary

The aim of the study is to find better and more specific non-invasive methods to diagnose and stage cardiac sarcoidosis with the use of advanced imaging modalities, simultaneous 3T MRI and PET. Cardiac sarcoidosis is a disease of possibly fatal outcome in young people. The use of a combined PET/MRI system with 18F-FDG and a new inflammation-tracer (18F-GE180) can become a future game changer.

Sarcoid induced focal inflammation in myocardium should show high 18F-GE180 uptake. 18F-GE180 PET scans will give reliable data about inflammatory sarcoidosis activity in the myocardium. 18F-GE180 PET is expected to improve diagnostic accuracy compared to 18F-FDG-PET and/or contrast enhanced MRI.

Conditions

  • Sarcoidosis
  • Cardiomyopathies

Interventions

DIAGNOSTIC_TEST

18F-FDG-PET/MRI

Contrast-enhanced MRI scanning after injection of 18F-FDG

DIAGNOSTIC_TEST

18F-GE180-PET/MRI

Contrast-enhanced MRI scanning after injection of 18F-GE180

Sponsors & Collaborators

  • Norwegian University of Science and Technology

    collaborator OTHER

  • University Hospital, Essen

    collaborator OTHER

  • St. Olavs Hospital

    lead OTHER

Principal Investigators

  • Edmund Søvik · St. Olavs Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-10-01
Completion
2020-10-01

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03561025 on ClinicalTrials.gov